Common breast cancer subtype may benefit from personalized treatment approach

April 4, 2014

The second-most common type of breast cancer is a very different disease than the most common and appears to be a good candidate for a personalized approach to treatment, according to a multidisciplinary team led by scientists at the University of Pittsburgh Cancer Institute (UPCI), a partner with UPMC CancerCenter.

Invasive lobular carcinoma, characterized by a unique growth pattern in breast tissue that fails to form a lump, has distinct genetic markers which indicate drug therapies may provide benefits beyond those typically prescribed for the more common . The results recently were published in Cancer Research and will be expanded upon on Tuesday at the American Association for Cancer Research (AACR) Annual Meeting 2014.

Patients with invasive lobular carcinoma typically are treated through surgical removal of the , followed by chemotherapy or hormone therapy or both, usually with the estrogen-mimicking drug tamoxifen or estrogen-lowering aromatase inhibitors, the same as patients with invasive .

"However, recent analyses suggest that a subset of patients with lobular carcinoma receive less benefit from adjuvant tamoxifen than patients with ductal carcinoma," said lead author Matthew Sikora, Ph.D., postdoctoral associate at UPCI, and recipient of this year's AACR-Susan G. Komen Scholar-in-Training Award for this research. "Our study, the largest of its kind, indicates an issue with the estrogen receptors inside lobular carcinoma cells and points to potential targets for drug therapy in future clinical trials, which we are developing."

Early studies in developing these potential targets are the topic of Dr. Sikora's AACR presentation, with a focus on a unique signaling pathway regulated by estrogen specifically in lobular cells.

Explore further: Breast cancer type linked to paternal cancer

Related Stories

Breast cancer type linked to paternal cancer

November 28, 2011

The risk of breast cancer is increased by genetic and lifestyle factors such as the inherited BRCA2 gene, age of having first child, or use of hormone replacement therapy (HRT). New research published in BioMed Central's ...

Low rates of recurrence with 'no ink' as margin in breast CA

February 14, 2014

(HealthDay)—Positive margins (ink on invasive carcinoma or ductal carcinoma in situ) are associated with increased risk of ipsilateral breast tumor recurrence (IBTR), according to consensus guidelines published online Feb. ...

Recommended for you

Current cancer drug discovery method flawed, study finds

May 2, 2016

The primary method used to test compounds for anti-cancer activity in cells is flawed, Vanderbilt University researchers report May 2 in Nature Methods. The findings cast doubt on methods used by the entire scientific enterprise ...

Shape of tumor may affect whether cells can metastasize

April 28, 2016

Only a few cells in a cancerous tumor are able to break away and spread to other parts of the body, but the curve along the edge of the tumor may play a large role in activating these tumor-seeding cells, according to a new ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.